Lysibody & Bacteriophage Therapy

Idea Brief

Lysibody & Bacteriophage Therapy is pioneering "recombinant immunotherapy" and lytic bacteriophage lysins, representing a groundbreaking immunotherapy option targeting Gram-negative bacteria. This innovation has the potential to revolutionize public health by combatting AMR diseases such as typhoid, TB, and sepsis, thereby strengthening immunity and reducing healthcare costs. Their locally developed technology emphasizes affordability and accessibility, simultaneously reducing import expenditures and elevating the nation's health and economy.